Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Extracellular Vesicle Proteomics in Substance Use Disorder

ABSTRACT: This study investigates the proteomic composition of extracellular vesicles (EVs) derived from postmortem prefrontal cortex brain tissues of individuals with substance use disorder (SUD) and matched controls.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Extracellular Vesicle

DISEASE(S): Substance Abuse

SUBMITTER: Carlos Gartner

LAB HEAD: Calvin Vary

PROVIDER: PXD061471 | Pride | 2025-05-14

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	gg_Wasif_102023_6600_IDA01.wiff	Wiff
	gg_Wasif_102023_6600_IDA01.wiff.scan	Wiff
	gg_Wasif_102023_6600_IDA02.wiff	Wiff
	gg_Wasif_102023_6600_IDA02.wiff.scan	Wiff
	gg_Wasif_102023_6600_IDA03.wiff	Wiff

Items per page:

1 - 5 of 74

Similar Datasets

Analysis of association between LPHN3 markers and substance use disorder

Project description:Genetic factors are strongly implicated in the susceptibility to develop externalizing syndromes such as attention deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, and substance use disorder (SUD). Variants in the ADGRL3 (LPHN3) gene predispose to ADHD and predict ADHD severity, disruptive behaviors comorbidity, long-term outcome, and response to treatment. In this study, we investigated whether variants within ADGRL3 are associated with SUD, a disorder that is frequently co-morbid with ADHD. Using family-based, case-control, and longitudinal samples from disparate regions of the world, recruited either for clinical, genetic epidemiological or pharmacogenomic studies of ADHD, we assembled recursive-partitioning frameworks (classification tree analyses) with clinical, demographic, and ADGRL3 genetic information to predict SUD susceptibility. Our results indicate that SUD can be efficiently and robustly predicted in ADHD participants. The genetic models used remained highly efficient in predicting SUD in a large sample of individuals with severe SUD from a psychiatric institution that were not ascertained on the basis of ADHD diagnosis, thus identifying ADGRL3 as a risk gene for SUD. Recursive partitioning analyses revealed that rs4860437 was the predominant predictive variant. This new methodological approach offers novel insights into higher order predictive interactions and offers a unique opportunity for translational application in the clinical assessment of patients at high risk for SUD

2020-04-01 | GSE112652 | GEO

Proteomics of Substance Use Disorder in the Dorsolateral Prefrontal Cortex

Project description:Ex vivo large-scale proteomic analysis using LC-MS/MS in postmortem brains of patients with substance use disorder and controls. Brain tissue was collected postmortem after consent from the next of kin. As part of the clinical information, medical records were obtained and a detailed psychological autopsy was performed on all participants by interviewing the next-of-kin. Information regarding the psychiatric clinical phenotypes (evidence of depression, mania, and psychosis) stressful life events, age of drug use onset, types of drugs used, smoking and drinking history, and any co-morbidities, was obtained. A diagnosis of substance use disorder was confirmed based on the psychological autopsy, detailed medical records, and review of all relevant case information by three psychiatrists at a consensus meeting. The cause of death was obtained from the medical examiner’s report and toxicological findings after death.

2021-09-10 | PXD025269 | Pride

Patient Navigation for Colorectal Cancer Screening for Patients With Mental Illness and/or Substance Use Disorder

Project description:The investigators propose to develop, implement, and evaluate a novel Colorectal (CRC) screening patient navigator program for patients with Mental Health (MH) and /or Substance Use Disorder (SUD) receiving care at Massachusetts General Hospital Charlestown. The study will involve randomly assigning eligible patients to early intervention or usual care/delayed intervention groups. The investigators believe this random assignment is ethical because Patient Navigation (PN) is an extremely limited resource, and all patients identified as eligible could not be contacted by the navigators in a short period of time. Thus the investigators will randomly assign access to PN during the study period, and then allow all patients to be navigated and screened after the study period is over. As a result, all eligible patients will be referred for PN, but the timing of the referral will be randomly assigned.

| 2251413 | ecrin-mdr-crc

Methamphetamine and Other Substance Use Disorder Genetics in Thailand

Project description:Methamphetamine and Other Substance Use Disorder Genetics in Thailand

| PRJNA955367 | ENA

Analysis of association between LPHN3 markers and substance use disorder

Project description:Analysis of association between LPHN3 markers and substance use disorder

| PRJNA448611 | ENA

Profiling of mRNA transcriptomic changes using RNA-seq in postmortem prefrontal cortex of subjects with alcohol use disorder

Project description:Purpose: The goal of this study to examine mRNA transcriptomic changes in reward-related brain regions of subjects with alcohol use disorder. Methods: Total RNAs were extracted from postmortem prefrontal cortex of 12 AUD and 12 control subjects. rRNA depletion RNA sequencing was performed and the sequence reads were processed using the bulk RNA-seq processing pipeline Pipeliner workflow (Federico et al. Front Genet 2019; 10, 614). AUD-associated mRNA transcriptomic changes were analyzed by the Limma-Voom method. Results: Differentially expressed mRNAs (absolute FC>2.0 & P<0.05) were identified in postmortem prefrontal cortex of subjects with alcohol use disorder (AUD). Chronic alcohol consumption may alter mRNA transcriptome profiles in reward-related brain regions, resulting in alcohol-induced neuroadaptations.

2021-10-13 | GSE182173 | GEO

Demographically Diverse Substance Use Disorder Cohorts of Dr. Stanley H. Weiss

Project description:Demographically Diverse Substance Use Disorder Cohorts of Dr. Stanley H. Weiss

| PRJNA671286 | ENA

Demographically Diverse Substance Use Disorder Cohorts of Dr. Stanley H. Weiss

Project description:Demographically Diverse Substance Use Disorder Cohorts of Dr. Stanley H. Weiss

| PRJNA671287 | ENA

Genetic analysis of Substance Use Disorder using the Indiana Biobank data

Project description:Genetic analysis of Substance Use Disorder using the Indiana Biobank data

| PRJNA869818 | ENA

Genetic analysis of Substance Use Disorder using the Indiana Biobank data

Project description:Genetic analysis of Substance Use Disorder using the Indiana Biobank data